undamentalytics Newsletter

Enright Patrick G: insider trades

Director at 4 companies we cover. 7 open-market purchases and 42 sales not made under a pre-set plan, reported from May 13, 2010 to December 15, 2025.

Would copying Enright Patrick G’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 5 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on May 14, 2010 into $97,244 by November 2, 2026, +14.8% a year. The copy held shares only 25% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $19,593, +4.2% a year (the S&P 500 held throughout made $88,857, +14.2% a year). Beta against the index was 0.25. Twelve months after each report, the average purchase was +135.1% against the S&P 500 (median +62.8%), and 60% beat it. Measured from the trade date, the insider’s own timing, the average was +128.8%. After their sales, the shares moved +0.8% against the index over 12 months on average (a negative figure means selling was the right call); 69% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$50.0k$100k$150k 201020122014201620182020202220242026 $97.2k$88.9k$19.6k
Copying Enright Patrick GS&P 500, same days investedS&P 500, held throughout $10,000 copying Enright Patrick G’s open-market purchases from May 14, 2010, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+14.8%
S&P 500, same days invested
+4.2% (held throughout +14.2%)
Time in shares
25%
Sharpe ratio (S&P 500)
0.53 (0.77)
Biggest drop (S&P 500)
−80% (−34%)
Market sensitivity (beta)
0.25
Purchases copied
6

Trade by trade

Enright Patrick G: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 6 −5.0% −4.9% 50% 4 −0.16 0.88 No reliable evidence
Purchases, 6 months after the report 6 +46.3% +36.8% 67% 4 1.90 0.15 No reliable evidence
Purchases, 12 months after the report 5 +135.1% +62.8% 60% 4 1.33 0.28 No reliable evidence
Purchases, 12 months after the trade 5 +128.8% +59.0% 60% 4 1.47 0.24 No reliable evidence
Sales, 3 months after the report 39 −1.6% −1.1% 56% 10 −0.99 0.35 No reliable evidence
Sales, 12 months after the report 39 +0.8% −17.0% 69% 10 0.07 0.95 No reliable evidence
Sales, 12 months after the trade 39 +2.1% −17.4% 67% 10 0.16 0.88 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Jazz Pharmaceuticals plc JAZZ —131May 13, 2010August 15, 2023
Corcept Therapeutics Inc CORT —111January 25, 2011March 20, 2017
Vera Therapeutics, Inc. VERA —40April 5, 2022December 15, 2025
Zenas Biopharma, Inc. ZBIO —10October 14, 2025October 14, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
December 15, 2025December 11, 2025 VERA Purchase $249,985 −11.8%not yetnot yet
October 14, 2025October 9, 2025 ZBIO Purchase $2,250,026 −30.5%−23.9%−22.1%
June 25, 2025June 23, 2025 VERA Purchase $5,277,598 +7.9%+62.8%+59.0%
August 15, 2023August 14, 2023 JAZZ Sale $171,457 −12.0%−47.5%−45.0%
February 8, 2023February 6, 2023 VERA Purchase $11,999,995 +2.1%+491.7%+414.8%
November 25, 2022November 22, 2022 JAZZ Sale $1,049,271 −8.9%−42.4%−36.4%
August 9, 2022August 8, 2022 JAZZ Sale $165,887 −0.7%−19.3%−23.4%
April 5, 2022February 10, 2022 VERA Purchase $4,999,995 −23.0%−65.9%−51.2%
August 12, 2019August 9, 2019 JAZZ Sale $98,482 −10.2%−29.8%−25.4%
August 13, 2018August 10, 2018 JAZZ Sale $239,052 −12.2%−27.7%−27.7%
August 14, 2017August 11, 2017 JAZZ Sale $94,248 −12.2%+2.2%+5.2%
March 20, 2017March 16, 2017 CORT Sale $2,683,353 +7.6%+58.0%+67.1%
March 15, 2017March 13, 2017 CORT Sale $6,093,672 +5.5%+67.1%+47.9%
March 10, 2017March 8, 2017 CORT Sale $7,312,500 −0.9%+47.9%+50.1%
February 27, 2017February 23, 2017 CORT Sale $22,025,000 +25.2%+51.9%+72.1%
November 25, 2016November 22, 2016 CORT Sale $345,166 −7.0%+77.8%+76.0%
November 21, 2016November 17, 2016 CORT Sale $5,198,432 −10.2%+76.0%+72.2%
November 17, 2016November 15, 2016 CORT Sale $1,669,093 −18.7%+60.2%+74.1%
August 17, 2016August 15, 2016 JAZZ Sale $86,373 −18.2%−7.2%−8.5%
February 12, 2016February 10, 2016 JAZZ Sale $1,179,233 +15.7%−13.4%−16.6%
January 7, 2016January 5, 2016 JAZZ Sale $1,380,880 +1.1%−29.5%−30.6%
December 3, 2015December 1, 2015 JAZZ Sale $1,528,857 −8.4%−37.7%−37.2%
November 12, 2015November 10, 2015 JAZZ Sale $1,352,877 −4.7%−25.5%−23.3%
October 7, 2015October 5, 2015 JAZZ Sale $1,337,877 +0.3%−16.9%−18.2%
September 3, 2015September 1, 2015 JAZZ Sale $1,659,873 −19.9%−41.3%−40.7%
August 31, 2015August 27, 2015 JAZZ Sale $71,345 −20.3%−40.7%−36.1%
July 8, 2015July 6, 2015 JAZZ Sale $1,771,082 −23.5%−26.6%−24.9%
June 3, 2015June 1, 2015 JAZZ Sale $1,787,357 +1.1%−16.1%−16.9%
May 13, 2015May 11, 2015 JAZZ Sale $1,761,834 +7.3%−15.6%−17.3%
April 8, 2015April 6, 2015 JAZZ Sale $1,691,446 −1.1%−22.6%−20.7%
March 24, 2015March 20, 2015 CORT Sale $6,264,139 +15.0%−22.8%−24.9%
March 4, 2015March 2, 2015 JAZZ Sale $1,760,002 +1.2%−26.4%−24.5%
February 12, 2015February 10, 2015 JAZZ Sale $1,668,557 +3.2%−22.2%−22.1%
January 7, 2015January 5, 2015 JAZZ Sale $1,602,499 +9.9%−17.0%−16.2%
December 16, 2014December 12, 2014 JAZZ Sale $400,600 +8.3%−20.1%−21.2%
December 3, 2014December 1, 2014 JAZZ Sale $1,727,430 −3.4%−21.5%−17.4%
November 12, 2014November 10, 2014 JAZZ Sale $1,710,866 −4.4%−23.3%−26.3%
October 8, 2014October 6, 2014 JAZZ Sale $1,605,600 −2.2%−20.5%−20.4%
September 4, 2014September 2, 2014 JAZZ Sale $1,629,397 +2.4%−1.1%+3.7%
August 14, 2014August 12, 2014 JAZZ Sale $144,734 +12.0%+16.1%+28.4%
May 5, 2014May 1, 2014 CORT Sale $1,025,678 not yetnot yetnot yet
April 3, 2014April 1, 2014 CORT Sale $1,070,000 not yetnot yetnot yet
March 7, 2014March 5, 2014 CORT Sale $1,000,715 not yetnot yetnot yet
March 4, 2014February 28, 2014 JAZZ Sale $85,280,113 −11.3%−3.4%−1.2%
August 14, 2013August 13, 2013 JAZZ Sale $87,590 +31.6%+67.8%+59.7%
March 7, 2013March 5, 2013 JAZZ Sale $46,624,000 +10.7%+136.1%+142.4%
March 9, 2012March 9, 2012 JAZZ Sale $56,994,000 −9.8%+7.0%+5.8%
January 25, 2011January 21, 2011 CORT Purchase $2,925,000 not yetnot yetnot yet
May 13, 2010May 11, 2010 JAZZ Purchase $6,999,997 +25.6%+211.0%+243.3%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Enright Patrick G traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.